Quick Answer
NovaBridge Biosciences reported Stockholders Equity of $201.16 million for fiscal year 2024.
NovaBridge Biosciences Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $201.16M | -17.1% |
| 2023 | $242.58M | -41.9% |
| 2022 | $417.81M | -41.6% |
| 2021 | $715.15M | -87.3% |
| 2020 | $5.63B | +376.6% |
| 2019 | -$2.03B | -113.0% |
| 2018 | -$955.10M | -218.6% |
| 2017 | -$299.80M | -1965.8% |
| 2016 | -$14.51M | — |
- NovaBridge Biosciences showed a decrease of -17.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2024 period, NovaBridge Biosciences’s stockholders equity has grown by 1486.2% (from -$14.51 million to $201.16 million).
- The most recent figure is from NovaBridge Biosciences’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 3, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: